Group 1 - Lin Qingxuan officially listed on the Hong Kong Stock Exchange on December 30, with a stock code of 02657.HK, opening at HKD 85 after an IPO price of HKD 77.77, reaching a market capitalization of HKD 12.35 billion on the first day [1] - The company generated significant revenue from its core product, camellia oil, which accounted for nearly 40% of total revenue, with projections indicating it will contribute 45.5% of revenue by the first half of 2025 [1] - Lin Qingxuan's revenue for the first half of 2025 is projected to be HKD 1.052 billion, a substantial increase of 98% year-on-year, with net profit expected to rise by 110.16% to HKD 182 million [1] Group 2 - The IPO raised approximately HKD 997 million, primarily for R&D in skincare technology, brand building, and retail expansion [2] - Notable institutional investors, including Fidelity and Dajia Life, subscribed for about USD 62 million, representing 44.43% of the total shares offered [2] - L'Oréal Group has indirectly become a shareholder in Lin Qingxuan through Shanghai Kaihui Chuangmei, highlighting the brand's significance in the high-end skincare market [3] Group 3 - The listing process took about seven months from the initial filing to the final listing, marking a new phase for Lin Qingxuan in its multi-brand and global expansion strategy [4] - The trend of Chinese beauty brands seeking capital through Hong Kong listings is growing, with other brands like Chando and Proya also filing for IPOs [4]
林清轩登陆港股，首日股价最高冲至91港元/股